Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ticagrelor Clear all
Completed Phase 3 Interventional Results available

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

NCT02325466
View directory record Official record
Conditions
Peripheral Artery Disease, Type 2 Diabetes
Interventions
Aspirin, Ticagrelor, Aspirin Placebo, Ticagrelor Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

NCT01883869
View directory record Official record
Conditions
Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
Interventions
ticagrelor, placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

NCT01603082
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Jul 22, 2026, 5:21 PM EDT
Not listed Phase 4 Interventional

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

NCT01869309
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

NCT02545933
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Prasugrel, Vorapaxar, Aspirin, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

NCT01732822
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
13,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
290
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jul 22, 2026, 5:21 PM EDT
Withdrawn Phase 4 Interventional

Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study

NCT01916902
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Interventions
Ticagrelor- Delayed Administration, Ticagrelor- Immediate Administration, Optical Coherence Tomography
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

GM03 - Platelet RNA Signatures of Aspirin

NCT05278637
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

NCT03489863
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

NCT01852175
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

NCT02214121
View directory record Official record
Conditions
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions
Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Cangrelor Ticagrelor Transition Study

NCT01766466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
cangrelor, Ticagrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

NCT02403830
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methylnaltrexone, Placebo, Morphine, Ticagrelor
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jul 22, 2026, 5:21 PM EDT
Completed No phase listed Observational

Platelet Reactivity After CABG

NCT01793597
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in African American Patients

NCT01523392
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Newark, Delaware • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Jul 22, 2026, 5:21 PM EDT
Terminated Phase 4 Interventional

Ticagrelor and Peripheral Arterial Disease

NCT02407314
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
Procedure · Device · Other + 1 more
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NCT02081443
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 180mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

NCT03247738
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Cangrelor, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 22, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
Ticagrelor, Comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

NCT02270242
View directory record Official record
Conditions
Cardiovascular Disease, Interventional Cardiology
Interventions
Aspirin, Placebo, ticagrelor
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Jul 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

NCT02053909
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 22, 2026, 5:21 PM EDT